Feb 18, 2011, 05.01 PM IST
Hyderabad-based biotechnology company Transgene Biotek plans to raise USD 40 million via global depositary receipt (GDR).
In an exclusive interview with CNBC-TV18's Ekta Batra and Reema Tendulkar, SS Marthi, Director of Transgene Biotek says, "The proposal is to raise USD 40 million via issuance of GDR. A part of this USD 40 million will be utilised for the present product line, which includes oncology drugs, active pharmaceutical ingredients (APIs), oral delivery platform of oral insulin, etc."
Going forward, the company is also looking at certain acquisitions, and, "the proceeds will be utilised for acquisitions as well," he adds.
The company is engaged in sales of medical diagnostic products and services.
Transgene Biote stock price
On December 06, 2013, at 11:43 hrs Transgene Biotek was quoting at Rs 3.57, up Rs 0.17, or 5.00 percent. The 52-week high of the share was Rs 5.08 and the 52-week low was Rs 1.71.
The company's trailing 12-month (TTM) EPS was at Rs 0.27 per share as per the quarter ended September 2013. The stock's price-to-earnings (P/E) ratio was 13.22. The latest book value of the company is Rs 43.82 per share. At current value, the price-to-book value of the company is 0.08.
Tags: Transgene Biotek, biotechnology company, global depositary receipt, Ekta Batra, Reema Tendulkar, SS Marthi
Action in Transgene Biotek
Video of the day
Dec 5 2013, 12:20
- in FII View
Dec 4 2013, 11:08
- in FII View
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.